ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B-Cell Targets"

  • Abstract Number: L17 • ACR Convergence 2024

    Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial

    Yiyi Yu1, Ruina Kong1, Xia Xu1, Suxuan Liu1, Qian Chen1, Xiaofang Li2, Ming Sun2, Jianmin Yang1, Dongbao Zhao1 and Jie Gao1, 1Changhai Hospital, Shanghai, China, 2Rui Therapeutics, Nanjing, China

    Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
  • Abstract Number: 0244 • ACR Convergence 2024

    Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series

    Pei-Hsinq Lai1, Cheng-Hsun Lu2 and Song-Chou Hsieh3, 1Taipei City Hospital, Taipei, Taiwan (Republic of China), 2National Taiwan University Hospital, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: Post-COVID interstitial lung disease (post-COVID ILD) is a critical sequelae yet the role of immunomodulatory therapies remains unclear. We explored to characterize post-COVID ILD…
  • Abstract Number: 1396 • ACR Convergence 2024

    Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis

    Samuel Bitoun1, Bineta Ly2, Audrey Paoletti2, Catherine Menier Menier3, Marc Pallardy4, Bernard Maillere5 and Xavier Mariette6, and ABIRISK consortium, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Rheumatology departement, Université Paris Saclay, Inserm UMR 1184,Hopital Bicêtre, APHP, FHU CARE, Le Kremlin Bicêtre, France, 31 CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, 4Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France, 5CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Rituximab (RTX) provides long lasting efficacy in the control of rheumatoid arthritis. Among factors associated with RTX failure are the occurrence of anti-drug antibodies…
  • Abstract Number: 2074 • ACR Convergence 2024

    Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy

    Ivana Ilic1 and Galina Marder2, 1Northwell, Brooklyn, NY, 2Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare multisystem inflammatory condition leading to significant disability. The management of IIM remains challenging. B cell targeting therapies are…
  • Abstract Number: 0002 • ACR Convergence 2024

    Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders

    Byeong Hyeok Choi1, Vincent M DeStefano2, Masayuki Wada2, Kevin G Pinz1, Greg Deener2, Nabil Hagag1, Ahmed Abdel-Razek1, Yu Ma3, Jing Luo3 and Yupo Ma2, 1iCell Gene Therapeutics Inc., Stony Brook, NY, 2iCell Gene Therapeutics, Inc., Stony Brook, NY, 3iCar Bio Therapeutics Ltd, Zhongshan City, Guangdong, China (People's Republic)

    Background/Purpose: CD19 single and BCMA-CD19 compound chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable activity against autoimmune disorders, although relapses with CD19 CAR…
  • Abstract Number: 0304 • ACR Convergence 2024

    Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio

    doryan Garcia Olivas1, Judith Hernández Sánchez1, luis Bausá Gimeno1, Javier Nóvoa Medina1, Sergio Machín1, Maria Ángeles Acosta-Mérida1, Diana Botello-Corzo1, daniel Batista Perdomo1, José Ángel Hernández Beriain2 and Beatriz Tejera Segura1, 1Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, 2Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain

    Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
  • Abstract Number: 1421 • ACR Convergence 2024

    Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease

    Coziana Ciurtin1, Lucia Martin-Gutierrez1, John Casement2, Kyle Thompson3, Fai Ng4, Andre van Maurik5 and Elizabeth Jury1, 1University College London, London, United Kingdom, 2Newcastle University, Newcastle, United Kingdom, 3Newcastle University, Newcastle, England, United Kingdom, 4Newcastle University, Newcastle upon Tyne, England, United Kingdom, 5Precision Medicine, GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: Sjögren disease (SD) is characterised by B-cell hyperactivity associated with increased levels of B-lymphocyte stimulator (BlyS), but there are no effective biologic treatments for…
  • Abstract Number: 2084 • ACR Convergence 2024

    Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study

    Edoardo Conticini1, Paolo Cameli1, Silvia Grazzini1, Miriana d'Alessandro1, Laura Bergantini1, Brunetta Porcelli1, Maria Antonietta Mazzei1, Luca Cantarini1, Elena Bargagli1 and Bruno Frediani2, 1Università di Siena, Siena, Italy, 2Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy

    Background/Purpose: Anti-synthetase syndrome (ASS) is a rare autoimmune disease characterized by the presence of anti-aminoacyl-transfer-RNA synthetase antibodies (ARS) and the involvement of muscles, skin, joints,…
  • Abstract Number: 0003 • ACR Convergence 2024

    CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases

    Máire F. Quigley1, Jennifer S. Michaelson1, Jeffrey Jones1, Farrukh T. Awan2, Geoffrey P. Shouse3, Yue Zhang1, Todd Shearer1, Judy Inumerable1, Irina M. Shapiro1, Patrick A. Baeuerle1 and Stephen Wax1, 1Cullinan Therapeutics, Inc., Cambridge, 2UT Southwestern Medical Center, Dallas, 3City of Hope Comprehensive Cancer Center, Duarte

    Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
  • Abstract Number: 0512 • ACR Convergence 2024

    Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients

    Jasmine Shwetar1, William Rigby2, Sladjana Skopelia-Gardner3, Abhimanyu Armarnani1, Kelly Ruggles1 and Gregg Silverman1, 1NYU Grossman School of Medicine, New York, NY, 2Dartmouth-Hitchcock, Norwich, VT, 3Dartmouth Hitchcock Medical Center, Hanover, NH

    Background/Purpose: Of all approved biologic therapies, other than anti-CD20 depletion only CTLA4-Ig/abatacept treatment reduces levels of pathologic autoantibodies. Herein, our primary goal has been to…
  • Abstract Number: 1533 • ACR Convergence 2024

    Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease

    Racquel Domingo-Gonzalez1, Isabelle Baribaud2, Shrishti Tyagi1, Kevin Hart1, Ryan Eberwine2, Angus Sinclair1, Albert Candia1, Bruce Keyt1, Merle Elloso2, Maya Kotturi1 and Mary Beth Harler1, 1IGM Biosciences, Inc., Mountain View, CA, 2IGM Biosciences, Inc., Doylestown, PA

    Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG mAbs has been employed for the treatment of autoimmune (AI) disease for ~20 years; however, many…
  • Abstract Number: 2257 • ACR Convergence 2024

    Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis

    Barbara Bayeh1, Fanny Neira1, Karina Bonfiglioli1, Nadia Aikawa2, ANA PAULA ASSAD1, Renata Miossi1, Fernando Souza3, Carlos Emilio Insfran Echauri1, Henrique Giardini1, Emily Figueiredo Neves Yuki1, Henrique Carriço Da Silva1, Andre Franco1, Diogo Domiciano1, Julio Moraes4, Eloisa Bonfa1, Carla Goncalves Schahin Saad3, Ana Cristina Medeiros-Ribeiro5 and Andrea Shimabuco3, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil

    Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…
  • Abstract Number: 0004 • ACR Convergence 2024

    Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells

    Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA

    Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…
  • Abstract Number: 0513 • ACR Convergence 2024

    Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting

    Ioasaf Karafotias1, Maryam Adas1, Katie Bechman1, Nicholas Williamson1, Mark Hughes1, Daksh Mehta2, Ritika Roy1, Sam Norton3 and James Galloway4, 1King's College London, London, United Kingdom, 2King's College Hospital, London, United Kingdom, 3King's College London, London, England, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose:  Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
  • Abstract Number: 1541 • ACR Convergence 2024

    Effect of Rituximab on Long-term Damage Acquisition in Patients with Systemic Lupus Erythematosus

    Amanda Brito1, Teresa Moitinho de Almeida2, Sofia Miranda3, Miriam Barreto Baié1, Daniel Calado3 and David Isenberg4, 1Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, 2Unidade Local de Saúde de Lisboa Ocidental, Lisboa, Portugal, 3Hospital do Divino Espírito Santo, Ponta Delgada, Portugal, 4University College London, London, United Kingdom

    Background/Purpose: B-cell depletion has been used to treat patients with systemic lupus erythematosus (SLE) for over twenty years, but we still lack studies that evaluate…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology